Panacea Biotec arm gets 8 USFDA observations for Baddi facility
Advertisement
Punjab: Panacea Biotec has recently announced that its material wholly-owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") has received eight observations from United States Food and Drug Administration (USFDA) at the end of the inspection.
The inspection was held at Panacea Biotec Pharma Limited's facility at Baddi, Himachal Pradesh, India between May 30, 2022 and June 08, 2022.
"At the end of inspection, PBPL was issued a 'FDA Form 483' with eight (8) observations which are related to improvements in existing procedures and are addressable," the company stated.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.